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SUMMARY
Liver metastasis is a leading cause of death in pa-
tients with colorectal cancer. We previously found
that colorectal cancer tumor-initiating cells (TICs)
expressing CD110, the thrombopoietin (TPO)-bind-
ing receptor, mediate liver metastasis. Here, we
show that TPO promotes metastasis of CD110+
TICs to the liver by activating lysine degradation.
Lysine catabolism generates acetyl-CoA, which is
used in p300-dependent LRP6 acetylation. This trig-
gers tyrosine phosphorylation of LRP6, ultimately
activating Wnt signaling to promote self-renewal
of CD110+ TICs. Lysine catabolism also generates
glutamate, which modulates the redox status of
CD110+ TICs to promote liver colonization and drug
resistance.Mechanistically, TPO-mediated induction
of c-myc orchestrates recruitment of chromatinmod-
ifiers to regulatemetabolic geneexpression.Our find-
ings, therefore, establish TPO as a component of the
physiological environment critical for metastasis of
colorectal cancer to the liver.
INTRODUCTION
Liver metastasis is the leading cause of death in patients with
colorectal cancer (CRC). The seeding and the outgrowth of
distant metastasis of cancer are dependent on tumor-initiating
cells (TICs) (Visvader and Lindeman, 2008; Pang et al., 2010)—
particularly,migrating TICs, a subset of TICswith amesenchymal
phenotype (Tang, 2012). A specialized microenvironment,
referred to as a metastatic niche, is critical for allowing the
outgrowth of metastatic nodules frommigrating TICs (Oskarsson
et al., 2014), but the niche components supporting liver metas-
tasis are mostly unknown.
In a previous study, we showed that migrating TICs that drive
livermetastasis of CRC express CD110, a thrombopoietin (TPO)-
responsive homodimeric receptor (Gao et al., 2013). The self-
renewal of hematopoietic stem cells requires a balance between
positive and negative signals downstream of the TPO/CD110
axis (Fox et al., 2002). Considering that TICs and stem cells share
many common features and that liver is the major organ produc-
ing TPO (Vigon et al., 1992), we speculated that TPO is a niche
component critical for liver metastasis of CRC. TPO recruits
CD110+TICs to the liver and promotes their self-renewal in a
paracrine manner (Gao et al., 2013). Such a finding is consistent
with the fact that CRC rarely metastasizes to the liver in patients
with chronic hepatitis and, therefore, low TPO levels (Martin
et al., 1997; Wang et al., 2012). Further support for the pro-
metastatic role of TPO comes from studies suggesting that
interleukin-6 (IL-6) produced in advanced stages of CRC (Knu¨p-
fer and Preiss, 2010) could increase hepatic TPO production and
cause thrombocytosis (Kaser et al., 2001), which, in turn, is an in-
dependent risk factor for CRCmetastasis (Voutsadakis, 2014). In
the current study, we examined the molecular mechanism(s) by
which hepatic TPO promotes liver colonization of CD110+TICs.
RESULTS
Lysine Catabolism Is Increased in CD110+TICs in Liver
Metastatic Lesions
In a previous study using an in vivo model of organ-specific
metastasis of CRC, we showed that CD110+TICs are respon-
sible for liver metastasis (Gao et al., 2013). In the current study,
we compared a transcription profile of CD110+ tumor cells
derived from the primary xenograft of two CRC liver metastasis
cell lines (CRC102-LM and CRC108-LM) with those from liver
metastasis, using global transcriptome analysis (Figure 1A).
The highest ranking genes were validated by qPCR (Figure S1A).
In the KEGG (Kyoto Encyclopedia of Genes and Genomes) anal-
ysis, the top enriched pathways included the p53 signaling
pathway, Wnt signaling pathway, and saccharopine pathway
(lysine degradation) (Figure 1B). A pilot experiment that inhibited
each of the three pathways showed the most robust reduction in
liver colonization by CD110+TICs upon inhibition of lysine catab-
olism (Figure S1B). Transcripts for most enzymes in lysine catab-
olism (AASS, AASDH, AADAT, BCKDH, ECHS1, and HMGCL)
and for lysine transporters (CAT1 and CAT2B) were increased
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Figure 1. TPO Initiates Lysine Catabolism in Colorectal CD110+TICs
(A) Comparison of gene expression profiles between CD110+TICs from primary tumors (PT) and from liver metastases (LM).
(B) KEGG pathway analysis showing differential gene expression between CD110+TICs from liver metastases and from primary tumors. L, liver parenchyma; M,
metastatic lesion.
(legend continued on next page)
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(Figures 1C and 1D). Consistent with the transcriptome results,
lysine degradation was also elevated in CD110+ cells from pe-
ripheral blood ofmicewith CRC102-LM andCRC108-LM tumors
(Figure S2A).
Next, we tested whether the TPO-CD110 axis initiates the
metabolic reprogramming in CD110+TICs. In comparison with
differentiated tumor cells, TICs aremore dependent on glycolysis
(Mao et al., 2013). In our experiments, both CD133+CD110+ and
CD133+CD110 subpopulations from primary CRC102 tumors
had a higher glycolytic rate than the corresponding CD133
cells. TPO treatment of CD110+ cells decreased lysine concen-
tration inculturemediumvia increasedcellular uptake (Figure1E),
without impairing glycolysis (Figure S2B). A significant increase
in the intracellular level of metabolic intermediates in lysine
metabolism (e.g., saccharopine, a-ketoadipate, glutamate, and
acetyl-coenzyme A [acetyl-CoA]) was observed as early as 6 hr
after TPO treatment (Figure 1F). The expression ofmost enzymes
involved in lysine catabolism showed a concurrent increase (Fig-
ures 1G and S2C). Differentiating CD110+TICs with serum signif-
icantly reduced the amount of lysine consumption following TPO
exposure (Figure S2D). This metabolic reprogramming could be
reversed by TPO withdrawal (Figure S2E). Similar results were
obtained with primary CRC105 tumor (data not shown).
Lysine degradation generates acetyl-CoA, which, in turn,
serves as a precursor in the citric acid cycle in mitochondria as
well as participates in fatty acid synthesis in cytoplasm and his-
tone acetylation in cell nucleus. Upon incubation of CD110+ cells
with 13C-Lys and TPO, we observed an increase in cytoplasmic
acetyl-CoA (Figure 1H). Unexpectedly, only <5% of lysine was
converted to fatty acid (Figure 1I). Expression of fatty acid syn-
thesis enzymes (ACC, ACLY, FAS, GPAT, and SCD) was sup-
pressed (Figures 1J and S2C). 13C-Lys metabolism provided
58.3% of the acetyl-CoA for the TPO-treated CD110+ cells, in
contrast to 21.6% prior to TPO treatment (Figure 1I). Therefore,
acetyl-CoA was the main end product of lysine metabolism.
Lysine Catabolism Is Indispensable for Liver
Colonization by CD110+TICs
Next, we examined the expression of AASS, the rate-limiting
enzyme in the lysine catabolism, in human samples of primary
CRC and metastatic nodules. AASS was positive in 82.3% of
liver metastatic nodules, 8.2% of primary tumors, and only
2.3% of lung metastatic lesions. No AASS expression was de-
tected in metastatic samples from lymph nodes and peritoneum
(Figure 2A). In liver metastatic nodules, AASS staining was more
evident at the invasive edge (Figure 2B). Higher AASS expression
in liver nodules was associated with shorter time to liver relapse
after resection (Figures 2C and S3) and poorer overall survival
(Figure 2C). The classic saccharopine pathway predominates
in the liver (Papes et al., 1999). Although AASS staining was
strongly positive in healthy liver parenchyma, its expression
was significantly lower in tumor-adjacent liver tissues (Figure 2D).
AASS expression was significantly higher in CD110+ metastatic
samples than in CD110 metastases (Figure 2E). Immunofluo-
rescence staining suggested colocalization of AASS with
CD110 in liver metastases but not in primary lesions (Figure 2F).
These results implied that lysine catabolism is essential for liver
colonization by CD110+TICs.
In NOG (NOD/Shi-scid/IL-2Rgnull) mice orthotopically im-
planted with CD110+ cells overexpressing GFP, dietary lysine
deprivation inhibited 90% of liver metastasis (Figure 2G) but
failed to affect tumor growth (Figure S4A), primary tumor entry
into circulation (Figure S4B, upper panel), or tumor cell extrava-
sation fromblood vessels (Figure S4B, lower panel). In a previous
study (Gao et al., 2013), we showed that CDCP1+ cells drive
CRCmetastasis to the lungs. In the current study, we transduced
parental CRC102 cells with retroviral vectors expressing a short
hairpin RNA (shRNA) targeting AASS under the control of a pro-
moter element responsive to either CD110 (cis-CD110-HSV1-
tk/shAASS) or CDCP1 (cis-CDCP1-HSV1-tk/shAASS) and im-
planted transduced cells orthotopically into NOG mice on a
normal diet. AASS knockdown decreased liver metastasis (Fig-
ure S4D, upper panel) without affecting primary tumor formation
(Figure S4C, upper panel), intravasation (Figure S4C, lower
panel), or lung metastasis (Figure S4D, lower panel). To examine
the role of lysine metabolism during different phases of liver
metastasis, we generated CD110+ cells expressing AASS
shRNA under the control of a doxycycline (Dox)-dependent pro-
moter (Figure S5A) and injected these cells via tail vein into mice
on a normal diet. Observation of liver colonization for various pe-
riods of time prior to Dox administration revealed increased liver
metastatic burden (Figures 2H and 2I). CD110+AASS+ cells were
uniformly distributed throughout micrometastases soon after
liver colonization. As the colonies grew, these cells progressively
segregated to the invasive front (Figure 2I). Dox administration
starting at 2 days or 7 days after inoculation inhibitedmicrometa-
stasis outgrowth and increased CD110+ cell apoptosis. In stark
contrast, Dox administration starting at 28 days after inoculation,
when metastatic nodules were large, did not affect metastatic
burden or survival of CD110+ cells (Figures 2H, S5B, and S5C).
Therefore, lysine catabolism plays an important role in the forma-
tion of micrometastases but not late metastatic foci.
Acetyl-CoA Derived from Lysine Catabolism Transfers
the Acetyl Group to LRP6 in a p300-Dependent Manner
TPO promotes CD110+TICs to self-renew, an essential capacity
for early metastasis (Gao et al., 2013). In the current study, we
found increased self-renewal of CD110+TICs in lysine-containing,
(C) Validation of upregulated lysine catabolism genes in CD110+TICs from liver metastases.
(D) Schematic diagram of genes encoding enzymes involved in lysine degradation that are significantly upregulated in CD110+TICs from liver metastases.
(E) Effects of TPO (0.1 ng/ml) on lysine consumption by CD110+ cells.
(F) Effects of TPO (0.1 ng/ml) on intracellular levels of saccharopine, a-ketoadipate, glutamate, and acetyl-CoA in CD110+ cells. conc, concentration.
(G) CD110+ cells from CRC102 were treated with 0.1 ng/ml TPO for 6 hr, and expression of lysine catabolism genes was measured using qPCR. CD110+ cells
from CRC105 were incubated with 0.1 ng/ml TPO and 13C-Lys for 6 hr.
(H) The amount and distribution of 13C-acetyl-CoA were measured by mass spectrometry and normalized to protein concentration. cps, counts per second.
(I) End products, quantified as a percentage of total radioactive end products, were measured by mass spectrometry.
(J) CD110+ cells from CRC105 were treated with 0.1 ng/ml TPO for 6 hr. Expression of fatty acid synthesis genes was measured using qPCR.
Values are mean ± SD. **p < 0.05. See also Figures S1 and S2.
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but not in lysine-free, mediumupon TPO treatment. Such effect of
lysine deprivation was rescued by adding either lysine or its meta-
bolic intermediates (a-aminoadipate or a-ketoadipate) but not
by adding acetoacetate (Figure 3A). The rescuing action of self-
renewal by a-aminoadipate or a-ketoadipate was attenuated
by knocking down HMGCL (Figure 3B), an enzyme that catalyzes
the cleavage of HMG-CoA to acetoacetate and acetyl-CoA
(Figure 1D).
Acetyl-CoA is a major acetyl donor in the acetylation of
histones and non-histone proteins (Kaochar and Tu, 2012).
Considering acetyl-CoA accumulation in cytoplasm (Figure 1H),
we spiked the TPO-treated CD110+ cells with 13C-lysine and
immunoprecipitated acetylated peptides from cytoplasmic ex-
tracts to identify candidates containing 13C-acetyllysine. One
of the proteins identified was LRP6, a co-receptor of Wnt
signaling crucial for self-renewal of colon TICs (Vermeulen
et al., 2010). In our experiments, the temporal profile of LRP6
acetylation synchronized with cytoplasmic acetyl-CoA increase
(Figure 3C). LRP6 was no longer acetylated in an AASS or
HMGCL mutant (Figure 3D). In CRC xenografts derived from
CRC102-LM or CRC105-LM cell lines, LRP6 acetylation was
detectable in CD110+TICs from liver metastases but not from
primary lesions (Figure S6A). Mass spectrometry of co-immuno-
precipitated samples revealed an interaction of LRP6 with p300,
a histone acetyltransferase (Ogryzko et al., 1996). The asso-
ciation between p300 and LRP6 was prominent upon TPO
exposure but lost in the absence of TPO (Figure 3E). Trans-
duction of CD110+TICs with either shRNA targeting p300 or a
Figure 2. Lysine Degradation Is Involved in Early Liver Colonization by CD110+TICs
(A) Proportion of AASS-positive cases in clinical samples from primary colorectal tumors (n = 64), liver metastases (n = 52), lung metastases (n = 23), lymph node
metastases (n = 25), and peritoneum metastases (n = 9).
(B) AASS immunostaining (arrows) in liver metastases from a patient with colorectal cancer.
(C) Kaplan-Meier analysis of liver metastasis-free survival (upper panel) and overall survival (lower panel) of patients with colorectal cancer on the basis of AASS
expression in liver metastases.
(D) Immunohistochemical analysis of AASS expression in normal liver and tumor-adjacent liver tissues.
(E) Relative levels of AASS expression in CD110 versus CD110+ liver metastasis samples.
(F) Co-immunofluorescent (co-IF) staining of AASS and CD110 in primary tumors and liver metastases.
(G) Mice were implanted orthotopically with CD110+ cells from CRC102-LM and then were randomized into groups receiving a standard or lysine-free diet (n = 5
per group). Representative bioluminescence images (upper panel) and bioluminescence quantification of liver sections (lower panel) are shown at different time
points. CD110+TICs expressingGFPwere allowed to colonize the liver for different lengths of time before Dox (40mg/kg) was administered to knock down AASS.
(H) Bioluminescence analysis (upper panel) and GFP imaging (lower panel) of liver colonization at the indicated time points.
(I) Immunostaining of AASS (upper panel) and co-IF analysis of AASS and CD110 expression (lower panel) in liver metastases at different time points.
Values are mean ± SD. **p < 0.05. Scale bars, 50 mm. See also Figures S3–S5.
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Figure 3. Lysine Degradation Provides Acetyl-CoA to Acetylate LRP6 in a p300-Dependent Manner
(A) CD110+ cells from CRC108 were cultured in lysine-deprived medium (DLys) and treated with 0.1 ng/ml TPO for 7 days. Cells were supplemented with 100 mM
lysine, a-aminoadipate, a-ketoadipate, or acetoacetate; and the percentage of oncosphere-forming cells was determined.
(B) CD110+ cells fromCRC108 cultured in lysine-deprived medium (DLys) were treated for 7 days with 0.1 ng/ml TPO and/or a siRNA against HMGCL. Cells were
supplemented with 100 mM a-aminoadipate or a-ketoadipate, and the percentage of oncosphere-forming cells was determined.
(C) Time course of cytoplasmic acetyl-CoA content (upper panel) and LRP6 acetylation (lower panel) in TPO-treated CD110+ cells. LRP6 acetylation was
measured by western blotting (WB) of the immunoprecipitated proteins as indicated. IP, immunoprecipitation.
(D) LRP6 acetylation in response to TPO (0.1 ng/ml) in CD110+ cells expressing AASS or HMGCL mutant (mu).
(E) Co-immunoprecipitation (Co-IP) of LRP6 and p300 in CD110+ cells treated with or without 0.1 ng/ml TPO for 48 hr.
(F) LRP6 acetylation in CD110+ cells treated with 0.1 ng/ml TPO and/or a shRNA against p300 or DHAT for 48 hr. WT, wild-type.
(G) IF staining of p300 in CD110+ cells expressing wild-type p300 or S89 mutants, following TPO treatment (0.1 ng/ml).
(H) Co-IP analysis of acetylated LRP6 and the p300-LRP6 complex in CD110+ cells treated for 48 hr with 0.1 ng/ml TPO and/or 5 mM Ro-31-8220.
(I) LRP6 acetylation in CD110+ cells expressing wild-type LRP6 or K802 mutants, following TPO treatment (0.1 ng/ml).
Values are mean ± SD. **p < 0.05. See also Figure S6.
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catalytically inactive p300 mutant (DHAT) decreased TPO-
induced LRP6 acetylation (Figure 3F).
P300 has been reported to localize exclusively in the nucleus
(Ogryzko et al., 1996). Surprisingly, p300 moved from the
nucleus into the cytoplasm when CD110+ cells were treated
with TPO in our experiments (Figure 3G). Protein kinase C
(PKC) represses transcriptional activity by phosphorylating
p300 on S89 (Yuan and Gambee, 2000). The TPO/CD110 axis
regulates PKC signaling (Hong et al., 1998). Therefore, we gener-
ated p300 mutants in which S89 was replaced with A or Q and
expressed them in CD110+ cells. In the presence of TPO, both
S89 mutants showed abundant nuclear localization but no
detectable cytoplasmic staining (Figure 3G). The PKC inhibitor
Ro31-8220 blocked TPO-induced S89 phosphorylation,
reduced the amount of p300 that co-immunoprecipitated with
LRP6, and inhibited LRP6 acetylation (Figure 3H), suggesting
that PKC signaling is required for TPO-induced p300-LRP6 inter-
action and LRP6 acetylation.
To identify the specific site(s) of TPO-induced acetylation on
LRP6, we overexpressed flag-tagged LRP6 in CD110+ cells.
Tandem mass spectrometry analysis identified an acetylation
site at K802 upon TPO treatment (Figure S6B). To confirm this
result, we generated LRP6 mutants in which K802 was replaced
with A or R and expressed these mutants in CD110+ cells. Upon
TPO treatment, acetylation was evident in wild-type LRP6 but
not either K802 mutants (Figure 3I). Next, we transfected wild-
type LRP6 or K802 mutants into CD110+ cells and orthotopically
implanted these cells into NOG mice. K802 mutation markedly
decreased liver colonization (Figure S6D, right panel) but did
not affect primary tumor formation (Figure S6C) or intravasation
by CD110+TICs (Figure S6D, left panel).
LRP6 Acetylation Stimulates LRP6 Activity and
Self-Renewal of CD110+TICs
Activation of LRP6 in canonicalWnt signaling requires phosphor-
ylation (Bilic et al., 2007). In our experiments with CD110+TICs,
TPO led to LRP6 phosphorylation at two key residues (Thr1479
and 1493), whereas no phosphorylation of K802 mutants was
detectable (Figure 4A). Consistent with the functional impor-
tance of LRP6 phosphorylation, TPO treatment of K802
mutant-expressing cells failed to activate TOP-FLASH reporter
expression (Figure 4B) and, therefore, did not affect b-catenin
accumulation in the cytosol (Figure 4D) and transcription of
Wnt target genes (Figure 4C). Both LRP6 phosphorylation (Fig-
ure S6E, left panel) and Wnt signaling activity (Figure S6E, right
panel) were higher in CD110+TICs from liver metastases than
from primary lesions. Next, we focused on casein kinase (CK),
which typically recognizes putative phosphorylation sites of
LRP6 (Davidson et al., 2005). TPO induced all four CK1s
(CK1a/ε/d/g) to co-immunoprecipitate with wild-type but not
the K802 LRP6 mutants (Figure 4E). Dominant-negative (DN)-
CK1a and DN-CK1g, but not DN-CK1d, blocked TPO-induced
LRP6 phosphorylation (Figure 4F).
To determine the role of acetylated LRP6 on self-renewal of
CD110+TICs, we gave mice limiting doses of CD110+ cells
that co-express exogenous TPO with wild-type LRP6 or K802
Figure 4. Effects of LRP6 Acetylation on LRP6 Activity and Self-Renewal of CD110+TICs
CD110+ cells expressing wild-type LRP6 or K802 mutants were cultured for 48 hr in the presence or absence of 0.1 ng/ml TPO.
(A) Phosphorylation of T1479, T1493, and S1490 was analyzed by western blotting (WB) of co-IP as indicated. WT, wild-type; IP, immunoprecipitation.
(B) Transcriptional activity of the TOP/FOP reporter plasmid was analyzed by luciferase reporter assays.
(C) Representative confocal images of b-catenin (green) and phosphorylated LRP6 (red).
(D) Expression of mRNA encoding Wnt target genes (cyclinD1, LEF1, and mPAR) was measured using qPCR.
(E) Co-IP analysis of the LRP6-CK1 complex in CD110+ cells expressing LRP6-flag (200 ng), K802A-flag (200 ng), K802R-flag (200 ng), and/or V5-CK1 (200 ng),
following treatment with TPO (0.1 ng/ml).
(F) Phosphorylation of T1479 and T1493 in CD110+ cells expressing DN-CK1 (200 ng) following treatment with TPO (0.1 ng/ml).
(G) TIC frequency of CD110+TICs co-expressing pcDNA3.0-TPO and wild-type LRP6 or K802 mutants was measured by limiting dilution assays in vivo.
(H and I) Liver colonization (H) and LRP6 phosphorylation in liver metastases (I) were determined by bioluminescence and IF in mice injected intravenously with
control (ctrl) CD110+ cells from CRC102 and CRC105 or cells transduced with pGL-DKK1 or shRNA against p300.L, liver parenchyma; M, metastatic lesion.
Values are mean ± SD. **p < 0.05. Scale bar, 10 mm. See also Figure S6.
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mutants. Tumors generated from a single CD110+ cell (with
limiting dilution) were transplanted into secondary recipients
(Figure S6F). When compared to the wild-type group, there
was a >10-fold decrease in the frequency of self-renewing cells
in the K802 mutant groups (Figure 4G). Suppression of LRP6
activity, either by overexpressing Dickkopf-1 (Dkk1) (Niehrs,
2006) or by knocking down p300 expression (Figure S6G),
decreased liver metastatic efficiency (Figure 4H). Immunohisto-
chemistry on liver metastases showed a decreased number of
CD110+pLRP6+ cells in mice treated with shp300 (Figure 4I).
These results suggest that p300-mediated acetylation is indis-
pensable for LRP6 activation to support metastatic colonization
by CD110+TICs.
TPO Reduces Oxidative Stress in CD110+TICs via the
Lys-Glu Pathway
Oxidative stress caused by tumor arrest in hepatic sinusoids and
reperfusion limits cancer metastasis (Jessup et al., 1999). In this
study, we induced hepatic ischemia in TPO+/+ or TPO/mice by
clamping the hepatic artery and portal vein for 3min. Glutathione
(GSH) is one of the most important antioxidant defenses against
oxidative stress in cancer cells. Within 3 days, primary CD110+
cultures with TPO/ ischemic livers showed substantial cell
death, with a time-dependent decrease in GSH. Co-culturing
these cells with TPO+/+ ischemic livers significantly enhanced
cell viability and increased GSH (Figure 5A; Figure 5B, upper
panel). Adding TPO to cultured CD110+ cells decreased intracel-
lular reactive oxygen species (ROS) (Figure 5C, upper panel),
increased GSH (Figure 5C, lower panel), and decreased their
sensitivity to exogenous ROS (H2O2) or peroxynitrite (Figure 5D).
Wnt/b-catenin signaling protects cells against oxidative stress
(Tao et al., 2013). Wnt signaling activity in CD110+ cells was
higher upon co-incubation with TPO+/+ than with TPO/
ischemic liver (Figure 5B, lower panel). The loss of CD110+ cell
viability upon AASS knockdown was rescued by the supplement
of glutathione but not Wnt3A (Figure 5E). Consistently, the pro-
tective effect of TPO was diminished by GSH depletion and
not affected by Wnt pathway inhibition (Figure 5F). Glutamate
is a by-product of lysine degradation and upregulates GSH syn-
thesis (Richman andMeister, 1975). In CD110+ cells treated with
Figure 5. Lys/ Glu Metabolism Promotes Survival of CD110+TICs during Liver Colonization
(A) CD110+ cells from CRC105 were co-cultured with ischemic TPO+/+ or TPO/ livers for 3 days, and then cell viability was measured by flow cytometry. 3Ds,
3 days.
(B) GSH content (upper panel) and activity of TOP/FOP reporter plasmid (lower panel) in CD110+ cells co-cultured with ischemic TPO+/+ versus TPO/ livers.
(C) Effects of TPO (0.1 ng/ml; 72 hr) on intracellular ROS (upper panel) and GSH (lower panel) in CD110+ cells. DCF-DA, 20,70-dichlorofluoresein diacetate.
(D) CD110+ cells were cultured for 72 hr with 0.1 ng/ml TPO and/or H2O2 (100 mM) or peroxynitrite (200 mM), and then cell viability was measured by flow
cytometry.
(E) CD110+ cells from the experiment in Figure 5A were treated with siRNA against AASS, AASS siRNA together with GSH (2 mM), or AASS siRNA together with
Wnt3A conditional medium. The cell viability was assessed by flow cytometry. ctrl, control.
(F) After treatment with BSO (10 nM) or pGL-DKK1, CD110+ cells were co-cultured with ischemic TPO+/+ livers for 3 days, and cell viability was measured by flow
cytometry.
(G) Comparison of GSH level in CD110+ cells treated for 72 hr with 0.1 ng/ml TPO and/or siRNA against AASS, BCKDH, ECHS1, or HMGCL.
(H) CD110+ cells from the experiment in Figure 5A were also treated for 3 days with SSZ (50 mM) or S-4-CPG (25 mM), after which GSH content (upper panel) and
cell viability (lower panel) were determined.
Values are mean ± SD. **p < 0.05.
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TPO, intracellular GSH was reduced by knockdown of AASS but
not BCKDH, ECHS1, or HMGCL (Figure 5G). System xc
 imports
cystine into cells in exchange for glutamate to provide cysteine,
the rate-limiting substrate in GSH synthesis (Lewerenz et al.,
2013). Adding the structurally unrelated system xc
 inhibitor sul-
fasalazine or S-4-carboxyphenylglycine abolished TPO-induced
GSHproduction (Figure 5H, upper panel) and sensitized CD110+
cells to TPO+/+ ischemic livers (Figure 5H, lower panel).
Many chemotherapeutic agents, including fluorouracil (5-FU),
produce antitumor activity by promoting ROS-dependent
apoptosis (Sangeetha et al., 1990). In this experiment, CRC102-
LM cells were transfected with a lentiviral vector in which the
shRNA targeting AASS is under the dual control of the CD110-
responsive promoter and the Tet-inducible activator rtTA (referred
to as pCRTA; Figure 6A) andwere orthotopically transplanted into
NOGmice. Upon establishment of liver metastases 4 weeks later,
mice were treated with 5-FU alone, Tet alone, or 5-FU plus Tet.
Treatment with 5-FU alone produced >82% tumor regression at
week 6 (Figure 6B) but significantly increased the percentage of
CD110+ cells in liver metastases (Figure 6C, lower panel). Recur-
rence (n = 7 for liver and n = 1 for peritoneum)was noted in 8 out of
10suchmice. In thesecases,bothGSH level andWntactivitywere
higher inCD110+cells in livermetastases than those in primary le-
sions (Figure 6D). Next, we examined the relative contribution of
GSHversusWntsignaling.Thesensitivity ofculturedCD110+cells
to 5-FU was greatly enhanced by GSH depletion with buthionine
sulfoximine (BSO) but not Wnt inhibition with DKK1 overexpres-
sion (Figure 6E, upper panel). Tet treatment alone did not affect
the development of tumor burden (Figure 6B), but it decreased
GSH level, as well as Wnt activity, in CD110+ cells from liver me-
tastases (Figure 6D). In stark contrast, treatment with 5-FU plus
Tet decreased the size of livermetastases (Figure 6B, lower panel)
as well as the percentage of CD110+ cells in liver metastatic
lesions (Figure 6C, lower panel). In vivo, Tet treatment enhanced
the sensitivity of isolated CD110+ cells to 5-FU exposure in a
manner dependent on GSH and not Wnt (Figure 6E, lower panel).
Therefore, recurrence was not noted in any subject.
TPO-Induced c-myc Recruits HBO1 to Mediate
Acetylation of H3K14 in Genes Encoding Enzymes
Involved in Lysine Catabolism and Fatty Acid Synthesis
c-myc is essential in the TPO-CD110 axis in stem cells (Chanpra-
sert et al., 2006). In our experiments, c-myc expression was
significantly upregulated by TPO, before lysine degradation
became detectable (1 hr versus 6 hr) (Figure 7A). Chromatin
immunoprecipitation-qPCR (ChIP-qPCR) (Figure S7A, upper
panel) and qRT-PCR analyses (Figure S7A, lower panel) revealed
TPO-induced binding of endogenous c-myc to promoters of
most, if not all, genes encoding enzymes involved in lysine
degradation and fatty acid synthesis. We examined the effects
of TPO treatment on the changes of histone markers. TPO
increased H3K14 acetylation in CD110+ cells in a c-myc-depen-
dentmanner, without affecting other histonemarkers (Figure 7B).
H3K14 acetylation is a hallmark of active transcription (Koch
et al., 2007). ChIP-qPCR analysis of c-myc binding sites in two
genes involved in lysine metabolism (AASS and BCKDH) and
two genes encoding enzymes involved in fatty acid synthesis
(ACC and FAS) showed that c-myc increased acetylation of
H3K14 on these promoters (Figure 7C). This increase was
observed regardless of whether the genes were activated or
repressed. Confocal imaging showed nearly complete overlap
between c-myc and acetylated H3K14 in the nuclei of TPO-
treated CD110+ cells (Figure 7D).
HBO1 is required for most H3K14 acetylation events in
mammals (Kueh et al., 2011). As anticipated, we found binding
of HBO1 and c-myc to the promoters in AASS, BCKDH, ACC,
and FAS upon TPO treatment. HBO1 occupancy at these pro-
moters was significantly reduced when c-myc was knocked
down (Figure 7E, upper panel); knockdown of HBO1 did not
affect the binding of c-myc to these promoters (Figure 7E, lower
panel). Knockdown of either HBO1 or c-myc reduced the H3K14
acetylation at these promoters (Figure 7C). An HBO1 enzymatic
assay showed that the immunoprecipitated c-myc complex con-
tained Geminin-sensitive H3K14Ac acetyltransferase activity
(Figure S7B). In the next experiment, endogenous HBO1 knock-
down did not affect c-myc expression (Figure S7C). HBO1
knockdown repressed c-myc-dependent gene activation in
lysine catabolism but did not affect the genes involved in fatty
acid synthesis (Figure S7D), suggesting that HBO1 plays a
more important role in c-myc-mediated gene activation than in
gene repression.
Both H3K14 Acetylation and H3K27 Trimethylation Are
Required for c-myc-Mediated Repression of Genes
Encoding Enzymes Involved in Fatty Acid Synthesis
Our observation that H3K14 was acetylated at c-myc binding
sites, regardless of whether the genes were activated or
repressed, suggests that additional modifications are required
to determine the fate of c-myc targets. In the quantitative
ChIP (qChIP) experiment with CD110+ cells, TPO increased
H3K14Ac as well as H3K27 trimethylation (H3K27me3) on the
ACC and FAS promoters. In the promoters of AASS and BCKDH,
TPO increased H3K14Ac but not H3K27me3 (Figure 7F). Consis-
tently, confocal imaging showed only partial overlap of c-myc
Figure 6. Overcoming Chemoresistance of CD110+TICs by Abolishing the Lys/ Glu Protective Mechanism
(A–C) Schematic representation (A) of the parental lentiviral backbone (upper), the subsequent cloning intermediate (middle), and the final dual-promoter lentiviral
vector (lower) used in this study. CRC102-LM cells transfected with pCRTA were orthotopically implanted into NOGmice and allowed to form obvious tumors in
4 weeks. Mice were randomized into groups (n = 30 each) that received saline, 5-FU (50 mg/kg), Tet (4 mg/kg), or 5-FU+Tet. All treatments were repeated every
28 days for three cycles. Mice were monitored weekly for bioluminescence (B) and percentage of CD110+ cells (C) in primary lesions (upper panel) and liver
metastases (lower panel).
(D) GSH level (upper panel) and activity of TOP/FOP reporter plasmid (lower panel) in CD110+ cells from primary lesions and liver metastases.
(E) CD110+ cells in liver metastases from mice receiving saline were incubated ex vivo with 5-FU (20 mM), 5-FU plus 10 nM BSO, or 5-FU plus pGL-DKK1 (upper
panel). CD110+ cells in liver metastases from mice receiving Tet treatment were incubated ex vivo with 5-FU (20 mM), 5-FU plus 2 mMGSH, or 5-FU plus Wnt3A
conditional medium (lower panel). Cell viability was analyzed by flow cytometry 3 days after treatment.
Values are mean ± SD. **p < 0.05.
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Figure 7. TPO-Induced c-myc Coordinates H3K14 Acetylation and H3K27 Trimethylation to Regulate Genes Encoding Enzymes Involved in
Lysine Degradation and Fatty Acid Synthesis
(A) After CD110+ cells from CRC102 were treated with 0.1 ng/ml TPO for the indicated times, c-myc expression was determined by western blots.
(B) Western blots of different histone markers in CD110+ cells expressing c-myc siRNA, following TPO treatment (0.1 ng/ml). Levels of total histone 3, 4, or 2A
were used as controls.
(C) CD110+ cells from CRC102 were treated for 6 hr with 0.1 ng/ml TPO and/or siRNA against c-myc or HBO1. H3K14 acetylation was analyzed at the indicated
promoters by ChIP-qPCR.
(D) A representative confocal image of c-myc (green) and acetylated H3K14 (red) in CD110+ cells treated with 0.1 ng/ml TPO for 6 hr.
(E) CD110+ cells fromCRC105 were treated as described in Figure 7C; the association of endogenous c-myc and HBO1 at the indicated promoters was analyzed
with ChIP-qPCR.
(F) CD110+ cells from CRC105 were treated with 0.1 ng/ml TPO for 6 hr, and H3K27 trimethylation was analyzed at the indicated promoters using ChIP-qPCR.
(G) A representative confocal image of c-myc (green) and trimethylated H3K27 (red) in CD110+ cells treated with 0.1 ng/ml TPO for 6 hr.
(H) CD110+ cells from CRC102 were treated for 6 hr with 0.1 ng/ml TPO and/or c-myc siRNA. H3K27 trimethylation at the indicated promoters was analyzed by
ChIP-qPCR.
(I) CD110+ cells from CRC102 were treated for 6 hr with 0.1 ng/ml TPO and/or c-myc siRNA; recruitment of EZH2 by c-myc on the indicated promoters was
determined by sequential ChIP-qPCR. IgG, immunoglobulin G; Re-ChIP, sequential ChIP assay.
(J) CD110+ cells from CRC102 were treated for 6 hr with 0.1 ng/ml TPO and/or siRNA against c-myc or EZH2; c-myc responsiveness of the indicated promoters
was determined by luciferase (luc) reporter assays. b-gal, b-galactosidase.
(K) CD110+ cells from CRC105 were treated for 6 hr with 0.1 ng/ml TPO and/or siRNA against c-myc; the association of JMJD3 at the indicated promoters was
analyzed with ChIP-qPCR.
Values are mean ± SD. **p < 0.05. Scale bars, 5 mm. See also Figure S7.
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with H3K27me3 (Figure 7G). Knockdown of c-myc abolished
TPO-induced changes in H3K27me3 on the promoters of genes
related to fatty acid synthesis (Figure 7H). H3K27me3 is associ-
ated with gene repression in mammals (Barski et al., 2007). TPO-
induced upregulation of H3K27me3 was also observed in the
promoters of most other genes encoding enzymes involved in
fatty acid synthesis (Figure S7E).
H3K27 methylation is a reversible process that can be cata-
lyzed by either histone methyltransferase EZH2 or demethylases
such as the ubiquitously transcribed TPR gene on the X chromo-
some (UTX) and Jumonji-domain-containing protein 3 (JMJD3)
(Kuzmichev et al., 2002; Swigut and Wysocka, 2007). UTX was
hardly detectable in CD110+ cells and not affected by TPO treat-
ment (Figure S7F). Also, TPO treatment did not affect the expres-
sion of EZH2 or JMJD3. We performed sequential qChIP assays
using anti-c-myc antibody followed by anti-EZH2 antibody on
the ACC and FAS promoters. After TPO treatment, EZH2 was
pulled down in the anti-c-myc ChIP from CD110+ cells but not
from the c-myc knockdown clones (Figure 7I). A small interfering
RNA (siRNA) against c-myc increased ACC or FAS promoter
luciferase activity (Figure 7J); and concurrent inhibition of EZH2
with a siRNA led to further increase in promoter luciferase
activity. TPO treatment also significantly reduced the binding
of JMJD3 to the promoters of most genes encoding enzymes
in fatty acid synthesis but not the genes encoding enzymes
in lysine catabolism (Figures 7K and S7G); such effect was
abolished by c-myc knockdown. These results indicated that
c-myc recruits EZH2, as well as displaces JMJD3, to mediate
the repression of genes related to fatty acid synthesis.
DISCUSSION
In the current study, transcriptome analysis suggested activation
of lysine catabolism in CD110+TICs that drives liver metastasis.
This lysine degradation occurs primarily via the saccharopine
pathway in the liver (Higashino et al., 1965). Under normal condi-
tions, lysine degradation provides acetyl-CoA to the citric acid
cycle and fatty acid synthesis (Papes et al., 1999). We found
that, in CD110+TICs, acetyl-CoA is channeled to acetylate
LRP6 on K802 in a p300-dependent manner. This acetylation re-
cruits and activates CKs to phosphorylate LRP6, which, in turn,
activates b-catenin-dependent Wnt signaling and regulates self-
renewal in CD110+TICs (Vermeulen et al., 2010). In this sense,
lysine catabolism initiates liver colonization by coordinating the
production of acetyl-CoA. Our findings must be interpreted
within proper context: the lysine catabolism is likely to be impor-
tant only at the early stages of liver metastasis of CRC and not
essential for bulk growth of liver metastases. We detected
AASS expression in tissue from resected liver lesions (macro-
metastases) from CRC patients, and we found suppressed
AASS expression in tumor-adjacent liver tissues. We speculate,
albeit with limited evidence, that the suppression of AASS
expression in tumor-adjacent liver tissue reduces lysine utiliza-
tion in the body and is not released after the establishment of
metastatic nodules, thus providing enough lysine to help meta-
static CD110+TICs from primary lesions or metastatic sites to
form new metastases in the liver. Further studies are required
to define whether this is attributed to persistence of mutual
crosstalk between primary tumor and liver microenvironment.
Liver ischemia produced by metastatic tumor cells as they
arrest in hepatic microcirculation generates ROS and reactive
nitrogen species, which, in turn, could act as a barrier to liver
colonization (Jessup et al., 1999). Highly glycolytic TICs typi-
cally produce reducing species in order to strengthen antioxi-
dant defenses (Mao et al., 2013). Paradoxically, we found that
CD110+TICs exhibit spontaneous apoptosis when cultured
with TPO/ ischemic livers. It is possible that, in liver metastasis
of CRC, lysine catabolism provides an antioxidant strategy
because the saccharopine pathwaymay serve to generate gluta-
mate (Papes et al., 2001), which promotes GSH synthesis by
enhancing cystine uptake (Lewerenz et al., 2013) and by
competing with GSH in the regulatory site of gGCS (Richman
and Meister, 1975). In this way, lysine catabolism could increase
the ability of CD110+TICs to maintain redox balance during liver
colonization. Increased GSH synthesis may confer an additional
benefit to the cancer: GSH could conjugate to, and thus activate,
anticancer drugs through the action of GSH S-transferases (Liu
et al., 2010). Our data well explain why most CRC patients un-
dergo hepatic relapse even after receiving curative resection
and radiochemotherapy. Disrupting the lysine-glutamate flow
represents a novel therapeutic approach to prevent post-thera-
peutic recurrence.
TPO could rapidly induce c-myc expression in CD110+TICs
(Chanprasert et al., 2006), and this induction correlates with
large-scale changes in histone modifications (Knoepfler et al.,
2006). Our results suggest that direct interaction between
c-myc and HBO1, a lysine acetyltransferase essential for
H3K14 acetylation and multipotency in embryonic stem cells
(Kueh et al., 2011), induces local H3K14 acetylation, regardless
of whether the target genes are activated or repressed. We
showed that HBO1 is broadly required for c-myc-mediated
gene activation but not c-myc-dependent gene repression. We
also found increased H3K27 trimethylation in repressed targets
of c-myc. For many target genes, c-myc represses expression
by recruiting H3K27 methyltransferase EZH2, as well as by dis-
placing the demethylase JMJD3. Based on these results, we
speculate that repressive H3K27 trimethylation overrides stimu-
latory H3K14 acetylation, resulting in gene silencing in c-myc-
associated chromatin. Such a regulatory system is, in some
way, similar to bivalent domains in embryonic-stem-cell devel-
opmental genes (Bernstein et al., 2006), where trimethylation of
H3K27 and of H3K4 occur together. In this system, the target
genes are silenced but poised for activation, ensuring rapid tran-
sition between metabolic states needed to support the dynamic
interplay between TIC pluripotency and differentiation during
liver colonization.
EXPERIMENTAL PROCEDURES
Cell Culture
Human CRC tissues were obtained with informed consent and in accordance
with the ethical standards of the Changzheng Hospital Institutional Review
Board. Primary CRC cells (CRC102, CRC105, and CRC108) and their liver-
specific variants (CRC102-LM, CRC105-LM, and CRC108-LM) were main-
tained as previously described (Gao et al., 2013). CRC105 cells have wild-type
adenomatous polyposis coli (APC) and b-catenin, while CRC102 and CRC108
cells harbor mutated APC (codon 1197, CTC/ TTT) and b-catenin (codon 41,
ACC / GCC), respectively. When magnetic-activated cell sorting (MACS)
was used to sort for CD110+ cells, dissociated tumor cells were incubated
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with a monoclonal CD110 antibody labeled with MicroBeads (Miltenyi Biotec)
for 30min at 4C, followed by cleavage of theMicroBeads. For Lys deprivation,
cells were cultured with lysine-depleted DMEM (Thermo Scientific). Lysine,
a-aminoadipate, a-ketoadipate, and acetoacetate were purchased from
Sigma-Aldrich. For siRNA inhibition studies, cells were transfected with vali-
dated human AASS, HMGCL, LRP6, p300, c-myc, HBO1, and EZH2 siRNA
or negative control siRNA (Ambion) at a final concentration of 100 nM in the
presence of an Oligofectamine reagent (Invitrogen).
Animal Studies
All animal protocols were approved by the Institutional Animal Care and Use
Committee for Second Military Medical University. The thrombopoietin
null (TPO/) mice were purchased from Genentech. All in vivo experiments
were performed in 4-week-old NOG mice. To generate orthotopic tumors,
we injected suspensions of the indicated cells into the cecal wall after laparot-
omy. In experimental metastasis assays, 1 3 105 CD110+ cells were injected
into the lateral tail vein of NOGmice. The GFP-lentiviral transduction facilitated
bioluminescence monitoring (Nikon, Nippon Kogaku) of tumor size and inci-
dence of liver metastases.
Statistical Analysis
All statistical analyses were carried out with SPSS software. Disease-free
survival and overall survival curves were estimated with the Kaplan-Meier
method. ANOVA, Student’s t test, and Dunnett’s multiple comparison tests
were used to compare mean values. Data are presented as mean ± SD. A
p value < 0.05 was defined as statistically significant.
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